Caught my eye
-
Caught my eye — 8/9/24
Read more: Caught my eye — 8/9/24A pretty quiet week for pharma health policy but there are a few things I think you should know … The Auchincloss Venn Diagram. Brian Reid improved upon Congressman Auchincloss’s diagram and I think it provides a great way to think about pharmacy benefit manager (PBM) reform. No chicken, no egg – straight to the…
-
Caught my eye, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, State-based Reform, UncategorizedCaught my eye — 08/02/24
Read more: Caught my eye — 08/02/24Up, up and away. Earlier this week, the Centers for Medicare & Medicaid Services (CMS) announced initial premium information for the 2025 Medicare prescription drug benefit. The base beneficiary premium went up 6% or $2.08 to $36.78. Which sounds okay until you realize that 6% is a capped amount due to the Inflation Reduction Act.…
-
Caught my eye — 07/26/24
Read more: Caught my eye — 07/26/24Let’s be honest, health policy has sort of taken a backseat when it comes to what we’re all tracking these days. And that’s okay. If you’ve taken a deserved timeout, let me catch you up on what caught my eye. Ice Ice Baby. The House of Representatives Committee on Oversight and Accountability released a report…
-
Caught my eye — 7/12/24
Read more: Caught my eye — 7/12/24Maybe it’s summer, maybe it’s an existential crisis but none of the news of late feels all that important. Not on my bingo card. This week the Federal Trade Commission released an interim report on pharmacy benefit managers (PBMs). It was a takedown of the industry but that’s just words, not action. Unless it isn’t.…
-
Caught my eye — 06/07/24
Read more: Caught my eye — 06/07/24A relatively quiet week around these parts. I think everyone is so ASCO’d and BIO’d that policy is taking a quick breather. A PDAB will do you. The National Pharmaceutical Council put out a nice round-up comparing four prescription drug affordability boards. The chart is my favorite part – Extra, extra. Elevance Health, a health…
-
Caught my eye — 05/31/24
Read more: Caught my eye — 05/31/24Trying to change my view. I don’t know if it is summer malaise setting in or an existential crisis about the state of society, sometimes it is hard to tell. Earlier this week, Jessica Yellin of News Not Noise pointed out that a lot of articles are really negatively titled and it is driving a…
-
340B, Caught my eye, Drug Prices, Inflation Reduction Act, Medicare Negotiation, Pharmacy Benefit Managers, State-based ReformCaught my eye — 05/24/24
Read more: Caught my eye — 05/24/24Coulda, woulda, shoulda. On Tuesday, the Senate Judiciary committee had a hearing on prescription drug prices. It became clear that comparisons to international prices remain a focus but so is patent abuse. I am not sure that’s a fair characterization. What companies are doing is legal and I’m not sure they’d be doing their fiduciary…
-
Caught my eye — 5/17/24
Read more: Caught my eye — 5/17/24Crab cakes and … horse racing. That’s what Maryland does. Mine will come with a side of Smith Island cake which I’m making tomorrow morning. Wish me luck. Odds aren’t stacked. The Centers for Medicare & Medicaid Services (CMS) announced that the Medicaid rule won’t contain the stacking provision. A little odd to pre-announce it,…
-
340B, Caught my eye, Drug Prices, Employers, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Reference Pricing, ValueCaught my eye — 5/10/24
Read more: Caught my eye — 5/10/24Back to back. Arnold Ventures put out the latest anti-pharma talking points (h/t Brian Reid) and here were two back to back – Here’s the problem, it really isn’t about the cost of drugs. I mean you could take that drug price and reduce it 98% and the 25% cost share would still be too…
-
Caught my eye — 5/3/24
Read more: Caught my eye — 5/3/24LDT. Not a sandwich, not a drink but laboratory developed tests. On Monday, the Food and Drug Administration (FDA) put out the long anticipated final rule on LDTs. If you’re more of a prescription drug policy person, get used to following LDT policy. We’ve moved from tests that are nice but, even if you have…
Latest news
- Caught my eye — 1/24/25
- Caught my eye — 1/16/25
- Caught my eye — 1/10/25
- Caught my eye — 12/20/24
- Nurturing the Potential of Biosimilars
Categories
- 340B (31)
- Affordable Care Act (3)
- Alzheimer's (4)
- Biosimilars (19)
- Caught my eye (53)
- Chevron Deference (2)
- CMMI (8)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (28)
- Drug shortages (7)
- DTC (2)
- Employers (7)
- Generics (4)
- Health Equity (3)
- Healthcare Costs (24)
- ICER (7)
- Importation (2)
- Inflation Reduction Act (42)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (3)
- Medicare Advantage (13)
- Medicare Negotiation (44)
- Medicare Part D (40)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (6)
- Obesity (18)
- On the Horizon (1)
- Orphan Drugs (2)
- Pharmacy Benefit Managers (25)
- Reference Pricing (4)
- State-based Reform (13)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (2)
- Value (8)